X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1343) 1343
Publication (54) 54
Newsletter (45) 45
Newspaper Article (28) 28
Book Review (15) 15
Book Chapter (12) 12
Magazine Article (9) 9
Book / eBook (1) 1
Dissertation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (968) 968
glycopyrrolate (670) 670
male (584) 584
female (569) 569
index medicus (414) 414
adult (377) 377
glycopyrrolate - administration & dosage (353) 353
middle aged (336) 336
glycopyrrolate - pharmacology (328) 328
glycopyrrolate - therapeutic use (323) 323
aged (216) 216
heart rate - drug effects (200) 200
double-blind method (199) 199
glycopyrrolate - adverse effects (192) 192
pulmonary disease, chronic obstructive - drug therapy (192) 192
treatment outcome (181) 181
animals (174) 174
anesthesiology (171) 171
atropine (165) 165
muscarinic antagonists - administration & dosage (163) 163
muscarinic antagonists - therapeutic use (156) 156
respiratory system (151) 151
time factors (139) 139
adolescent (134) 134
lung diseases, obstructive (132) 132
atropine - pharmacology (131) 131
copd (128) 128
obstructive pulmonary-disease (125) 125
pharmacology & pharmacy (123) 123
pyrrolidines - pharmacology (123) 123
administration, inhalation (121) 121
bronchodilator agents - administration & dosage (111) 111
anesthesia (110) 110
chronic obstructive pulmonary disease (109) 109
child (104) 104
muscarinic antagonists - adverse effects (103) 103
blood pressure - drug effects (102) 102
drug combinations (102) 102
efficacy (102) 102
tiotropium (102) 102
drug therapy (93) 93
double-blind (92) 92
dose-response relationship, drug (90) 90
research (89) 89
glycopyrronium (88) 88
safety (88) 88
care and treatment (87) 87
pulmonary disease, chronic obstructive - physiopathology (84) 84
cross-over studies (78) 78
muscarinic antagonists - pharmacology (78) 78
preanesthetic medication (76) 76
bronchodilator agents - therapeutic use (75) 75
drug therapy, combination (73) 73
child, preschool (72) 72
surgery (72) 72
bronchodilator agents - adverse effects (71) 71
atropine - administration & dosage (70) 70
medicine, general & internal (70) 70
children (69) 69
pediatrics (69) 69
dosage and administration (67) 67
management (67) 67
indacaterol (66) 66
severity of illness index (66) 66
indans - administration & dosage (64) 64
quinolones - administration & dosage (64) 64
analysis (63) 63
neostigmine (62) 62
premedication (61) 61
clinical trials (60) 60
parasympatholytics - pharmacology (58) 58
veterinary sciences (58) 58
pulmonary disease, chronic obstructive - diagnosis (57) 57
infant (56) 56
neostigmine - pharmacology (56) 56
prospective studies (54) 54
young adult (53) 53
atropine - therapeutic use (52) 52
clinical trials as topic (52) 52
formoterol (51) 51
glycopyrrolate - pharmacokinetics (51) 51
health aspects (51) 51
hyperhidrosis - drug therapy (51) 51
indans - therapeutic use (51) 51
pharmacokinetics (51) 51
quinolones - therapeutic use (51) 51
sialorrhea - drug therapy (51) 51
dermatology (50) 50
hyperhidrosis (50) 50
forced expiratory volume (49) 49
lung - drug effects (49) 49
sialorrhea (49) 49
drug administration schedule (48) 48
aged, 80 and over (47) 47
diseases of the respiratory system (47) 47
dogs (47) 47
medical research (47) 47
pharmaceutical industry (47) 47
adrenergic beta-2 receptor agonists - administration & dosage (46) 46
injections, intravenous (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1356) 1356
German (25) 25
Korean (19) 19
Spanish (10) 10
Danish (7) 7
French (7) 7
Japanese (7) 7
Hungarian (3) 3
Czech (2) 2
Portuguese (2) 2
Russian (2) 2
Italian (1) 1
Norwegian (1) 1
Polish (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 4, pp. 584 - 592
Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2 -agonist indacaterol... 
Pulmonary/Respiratory | QVA149 | Tiotropium | Chronic obstructive pulmonary disease | Exercise | Hyperinflation | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | DAILY NVA237 | EFFICACY | SAFETY | BRONCHODILATION | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TWICE-DAILY SALMETEROL | ONCE-DAILY INDACATEROL | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Indans - therapeutic use | Lung Volume Measurements | Vital Capacity - drug effects | Quinolones - adverse effects | Spirometry - methods | Quinolones - therapeutic use | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Cross-Over Studies | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Confidence intervals | Drug therapy
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 03/2015, Volume 79, Issue 3, pp. 492 - 500
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 126, pp. 105 - 115
Abstract Background The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg... 
Pulmonary/Respiratory | Muscarinic antagonists | Co-Suspension™ Delivery Technology | Metered dose inhaler | β2-agonist | COPD | agonist | INDACATEROL | TWICE-DAILY FORMOTEROL | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | QVA149 | COMBINATION | ONCE-DAILY TIOTROPIUM | Co-Suspension (TM) Delivery Technology | THERAPY | RESPIRATORY SYSTEM | GLYCOPYRRONIUM | beta-agonist | COPD PATIENTS | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Muscarinic Antagonists - therapeutic use | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers - utilization | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Formoterol Fumarate - pharmacology | Drug Tolerance | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Tiotropium Bromide - pharmacology | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Smoking - epidemiology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Glycopyrrolate - pharmacology | Aged | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Medical colleges | Formoterol | Lung diseases, Obstructive | Care and treatment | Respiratory therapy | Drugs | Drug delivery systems | Effectiveness | Statistical analysis | Lung diseases | Clinical trials | Glycopyrrolate | Long term | Side effects | Randomization | Dyspnea | Technology | Obstructive lung disease | Chronic obstructive pulmonary disease | Safety | Drug therapy | Respiration
Journal Article
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 02/2015, Volume 29, Issue 2, pp. 278 - 282
Journal Article
Thorax, ISSN 0040-6376, 04/2015, Volume 70, Issue 4, pp. 311 - 319
Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the... 
INDACATEROL | THERAPY | RESPIRATORY SYSTEM | DAILY SALMETEROL | DUAL BRONCHODILATION | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | OUTCOMES | GLYCOPYRRONIUM | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Indans - therapeutic use | Vital Capacity - drug effects | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Formoterol | Indacaterol | Dosage and administration | Diagnosis | Quality of life | 1506 | Chronic Obstructive Pulmonary Disease | COPD Pharmacology
Journal Article